199 related articles for article (PubMed ID: 31585917)
1. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
2. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
3. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
4. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
5. SETD2-dependent H3K36me3 plays a critical role in epigenetic regulation of the HPV31 life cycle.
Gautam D; Johnson BA; Mac M; Moody CA
PLoS Pathog; 2018 Oct; 14(10):e1007367. PubMed ID: 30312361
[TBL] [Abstract][Full Text] [Related]
6. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
[TBL] [Abstract][Full Text] [Related]
7. A New Chromatin-Cytoskeleton Link in Cancer.
Giaccia AJ
Mol Cancer Res; 2016 Dec; 14(12):1173-1175. PubMed ID: 27528705
[TBL] [Abstract][Full Text] [Related]
8. SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
Fahey CC; Davis IJ
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28159833
[TBL] [Abstract][Full Text] [Related]
9. Roles of SETD2 in Leukemia-Transcription, DNA-Damage, and Beyond.
Skucha A; Ebner J; Grebien F
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818762
[TBL] [Abstract][Full Text] [Related]
10. Structure/Function Analysis of Recurrent Mutations in SETD2 Protein Reveals a Critical and Conserved Role for a SET Domain Residue in Maintaining Protein Stability and Histone H3 Lys-36 Trimethylation.
Hacker KE; Fahey CC; Shinsky SA; Chiang YJ; DiFiore JV; Jha DK; Vo AH; Shavit JA; Davis IJ; Strahl BD; Rathmell WK
J Biol Chem; 2016 Sep; 291(40):21283-21295. PubMed ID: 27528607
[TBL] [Abstract][Full Text] [Related]
11.
Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between the H3K36me3 and H4K16ac histone epigenetic marks in DNA double-strand break repair.
Li L; Wang Y
J Biol Chem; 2017 Jul; 292(28):11951-11959. PubMed ID: 28546430
[TBL] [Abstract][Full Text] [Related]
13. Controllers of histone methylation-modifying enzymes in gastrointestinal cancers.
Li L; Song Q; Zhou J; Ji Q
Biomed Pharmacother; 2024 May; 174():116488. PubMed ID: 38520871
[TBL] [Abstract][Full Text] [Related]
14. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36.
de Almeida SF; Grosso AR; Koch F; Fenouil R; Carvalho S; Andrade J; Levezinho H; Gut M; Eick D; Gut I; Andrau JC; Ferrier P; Carmo-Fonseca M
Nat Struct Mol Biol; 2011 Jul; 18(9):977-83. PubMed ID: 21792193
[TBL] [Abstract][Full Text] [Related]
15. SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.
Tsang JY; Lai ST; Ni YB; Shao Y; Poon IK; Kwan JS; Chow C; Shea KH; Tse GM
Breast Cancer Res Treat; 2021 Jun; 187(2):339-347. PubMed ID: 33844099
[TBL] [Abstract][Full Text] [Related]
16. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
17. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
[TBL] [Abstract][Full Text] [Related]
18. SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
Zhu K; Lei PJ; Ju LG; Wang X; Huang K; Yang B; Shao C; Zhu Y; Wei G; Fu XD; Li L; Wu M
Nucleic Acids Res; 2017 Jan; 45(1):92-105. PubMed ID: 27614073
[TBL] [Abstract][Full Text] [Related]
19.
Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
[TBL] [Abstract][Full Text] [Related]
20. SETD2 histone modifier loss in aggressive GI stromal tumours.
Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
